Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD33 CAR-T for Relapsed/Refractory AML
NCT05445765Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ICG165 in acute myeloid leukemia (AML), sponsored by iCell Gene Therapeutics. Primary endpoint: Number and incidence of adverse events after anti-CD33 CAR infusion at 1 year. Status: unknown.
02
Drugs
ICG165
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05445765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445765.